Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review article

Pyrazolone structural motif in medicinal chemistry: Retrospect and prospect

Zefeng Zhao a, Xufen Dai a, Chenyang Li a, Xiao Wang a, Jiale Tian a, Ying Feng a, Jing Xie a, Cong Ma a, Zhuang Nie a, Peinan Fan a, Mingcheng Qian c, d, Xirui He e, Shaoping Wu a, *, Yongmin Zhang a, b, Xiaohui Zheng a

a School of Pharmacy, Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, Biomedicine Key Laboratory of Shaanxi Province, Northwest University, 229 Taibai Road, Xi'an, 710069, China
b Sorbonne Université, Institut Parisien de Chimie Moléculaire, CNRS UMR 8232, 4 Place Jussieu, 75005, Paris, France
c Department of Medicinal Chemistry, School of Pharmaceutical Engineering and Life Science, Changzhou University, Changzhou, 213164, Jiangsu, China
d Laboratory for Medicinal Chemistry, Ghent University, Otsjeramsesteenweg 460, B-9000, Ghent, Belgium
e Department of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai, 519041, China

A R T I C L E   I N F O

Article history:
Received 22 October 2019
Received in revised form 14 November 2019
Accepted 14 November 2019
Available online 16 November 2019

Keywords:
Pyrazolone
Antimicrobial
Antitumor
CNS agents
Anti-inflammatory
Derivatives

A B S T R A C T

The pyrazolone structural motif is a critical element of drugs aimed at different biological end-points. Medicinal chemistry researches have synthesized drug-like pyrazolone candidates with several medicinal features including antimicrobial, antitumor, CNS (central nervous system) effect, anti-inflammatory activities and so on. Meanwhile, SAR (Structure-Activity Relationship) investigations have drawn attentions among medicinal chemists, along with a plenty of analogues have been derived for multiple targets. In this review, we comprehensively summarize the biological activity and SAR for pyrazolone analogues, wishing to give an overall retrospect and prospect on the pyrazolone derivatives.

© 2019 Elsevier Masson SAS. All rights reserved.

Contents

1. Introduction ........................................................................................................................................... 2
2. Synthetic strategies of pyrazolones ........................................................................................................ 2
3. Pharmacological profile of pyrazolones ................................................................................................. 2
   3.1. Antimicrobial agents ....................................................................................................................... 2
   3.1.1. Pyrazolones as antimicrobial agents and their SAR ................................................................. 3
   3.2. Antitumor agents ............................................................................................................................ 7
   3.2.1. Pyrazolones as antitumor agents and their SAR ................................................................. 7
   3.3. CNS agents .................................................................................................................................. 10
   3.3.1. Anticonvulsant agents ............................................................................................................. 10
   3.3.2. Antidepressant agents ............................................................................................................... 12
   3.3.3. Anti-amyotrophic lateral sclerosis agents ............................................................................. 12
   3.3.4. Anti-Alzheimer’s agents .......................................................................................................... 12
   3.3.5. Other CNS target agents .......................................................................................................... 12

* Corresponding author.
E-mail address: wushaoping@nwu.edu.cn (S. Wu).

https://doi.org/10.1016/j.ejmech.2019.111893
0223-5234/ © 2019 Elsevier Masson SAS. All rights reserved.
1. Introduction

Pyrazolones delegate a cluster of compounds with the nucleus of 1H-pyrazol-3-ol and pyrazolin-5-one (Fig. 1) which have been investigated because of their multiple features and applications. Since 1883, the synthesis of antipyrine (1) by Knorr, numerous attention has caused by the analgesic and antipyretic activities of pyrazolone analogues [1]. The discovery of these features encouraged the researches to synthesize other pyrazolone derivatives with similar behavior but with a better therapeutic action. Nowadays, multiple FDA approved drugs containing pyrazolone nucleus have been explored (Fig. 2), for instances, edaravone (2) has been used as free radical scavenger for the treatment of amyotrophic lateral sclerosis (ALS) [2], aminophenazone (3) with antipyretic and anti-inflammatory activities has been used in breath tests to measure the cytochrome P-450 metabolic activity in liver function evaluations [3], eltrombopag (4) has been used for the treatment of low blood platelet counts in adults with idiopathic chronic immune thrombocytopenia [4], dichloralphenazone (5) has been used for the relief of tension and vascular headaches [5], metamizole (6) has been used for perioperative pain, cancer pain, acute injury and other forms of pain and is considered as the strongest antipyretic [6]. Several investigational small molecules containing pyrazolone have been regarded as drug candidates including sulfamazine (7) [7], propyphenazone (8) [8] and nifenazone (9) [9].

Regarding pyrazolone derivatives, it is important to underline the enormous diversity of classes of synthetic pyrazolone published in existing studies. As for the pharmacology investigators, this review is a concise and critical account focusing on the properties of pyrazolone derivatives and potential targets to give a visual appreciation of the roles of pyrazolone group play in the bioactivity.

2. Synthetic strategies of pyrazolones

Recent advances in the synthesis of pyrazolones have been reported in the literature [12]. Condensation of hydrazines with [β-ketoester compounds is the classical method for the synthesis of pyrazolones (Scheme 1), the catalytic conditions are usually the use of organic base like piperidine or inorganic base like NaH in the system of the boiling ethanol or methanol solvent. The nucleus of pyrazolones has been widely used to ulteriorly synthesize broad range of derivatives including spiroheterocycles and acylation productions [13], which features multiple reactive sites. The electrophilic substitution at the C-4 position of pyrazolones is an effective synthetic route for the construction of pyrazolones linked with chiral groups and 4-disubstituted pyrazolones. In addition, as an important synthon, α, β-unsaturated pyrazolones (R1: C≡C−R′/C≡N−R′/C=O) can be transformed into diverse pyrazolones. When R1 is C≡C−R′, they can undergo 1,4-Michael addition as acceptors to generate 4-substituted pyrazole analogues.

3. Pharmacological profile of pyrazolones

The broad-spectrum of pharmacology properties about pyrazolone derivatives have been reported including antimicrobial, antitumor, CNS activity, anti-inflammatory, antioxidant, antitubercular, antiviral, lipid-lowering, antihyperglycemic and protein inhibitory activities.

3.1. Antimicrobial agents

Pyrazolone derivatives have been reported to show the significant antimicrobial activities against multiple types of bacteria and fungi. Generally, the antibacterial effect of pyrazolones is better than its antifungal effect, and the inhibitory activity on Gram positive (Gram +ve) and Gram negative (Gram −ve) strains was distinct as well. The bacterial cell membrane is generated with a dense wall comprising several peptidoglycan and teichoic acid layers [14-17]. In Gram +ve bacteria, the adsorption of the biocidal molecules is occurred on the lipoteichoic acid layer which is characterized by the charged nature and the ability to interact with the heteroatoms in the biocide molecules. While in the Gram −ve bacteria, the lipid layer is the target of the biocide molecules. The drug resistance of traditional antibiotics has aroused people’s anxiety about super-bacteria, and the attentions giving pyrazolones will pay a light in this field.

Fig. 1. Structure of 1H-pyrazol-3-ol and pyrazolin-5-one.
3.1.1. Pyrazolones as antimicrobial agents and their SAR

Nasser S. A. M. Khalil [18] described Schiff base compound 10 and its acetyl glucoside derivative 11 (Fig. 3) which exhibited the most potent inhibitory effect against the strains of *Penicillium italicum*, *Syncephalastrum racemosum*, *Aspergillus fumigatus*, *Bacillus subtilis*, *Staphylococcus aureus* and *Escherichia coli* at the dose of 400 μg/mL. SAR could be deduced that the analogues with non-substituted on ring A exhibited the strongest activity and the acetyl glucoside group was more helpful to promote the inhibitory effect than N-glucoside. It was notable that the possible intramolecular H-bonding formed by the carbonyl group and the NH moiety improved the inhibition and the triad of permeability, solubility, and potency of the analogues were changed accordingly [19].

In 2007, Padmavathi and colleagues [20] synthesized multiple amino-pyrazolone, amino-isoxazolone and amino-pyrimidinone analogues, and evaluated their bioactivities. Thereinto, the amino-pyrazolone derivatives 12 and 13 (Fig. 3) showed the most pronounced antimicrobial activity (Table 1). SAR study expatiated that the presence of pyrazole and the introducing of effective moieties including –COCH3, –CH3, –Cl and thiophene group on the scaffold of 4-aminoantipyrine showed significant inhibitory effect.

Aly and co-workers [21] synthesized antipyrine derivatives 14, 15, 16 and 17 (Fig. 3) which were regarded as the prospective inhibitor (Table 1). SAR investigation expatiated that the presence of pyrazole and the introducing of effective moieties including –COCH3, –CH3, –Cl and thiophene group on the scaffold of 4-aminoantipyrine showed significant inhibitory effect.

Hamama and teammates [22] described the antibacterial activity of several pyrazolone analogues, among which compound 18 (Fig. 3) was the most hopeful candidate against *E. coli* and *B. subtilis* with the inhibition zoom diameter values of 40 and 36 mm respectively at the concentration of 100 ppm, which was approximately twofold to the reference drug ampicillin. The initiatory SAR can be considered as the introduction of piperidine group which was helpful to improve the antibacterial effect.

Active antimicrobial compounds 19 and 20 produced by Rasa-palli et al. [23] (Fig. 3) exhibited noticeable biofilm activity towards *S. aureus* strains (Table 2). Compound 19 suppressed biofilm formation of *Staphylococcus epidermidis* as well. SAR study suggested that the antibacterial scaffold can be acquired by condensation of the carbonyl compounds with the active methylene group on pyrazolone, and the 4-Cl and 2-Br substituted groups on A ring were proved to be the potential active modification for further development.

Gadhave and colleagues [24] synthesized multi-fluorinated pyrazole-pyrazolone and chromone-pyrazolone compounds 21, 22, 23 and 24 (Fig. 3) which exerted favorable antibacterial effects (Table 1), whereas all the compounds exhibited poor antifungal activity profile. Regarding SAR, it can be speculated as that multifluorinated substitution was contributive to antibacterial while further modification was needed to improve the antifungal effect.

Narayana Rao et al. [25] designed and synthesized several pyrazolone analogues 25, 26, 27 and 28 (Fig. 3) with favorable activity (Table 1). As for SAR, the authors disclosed that the amino group on the A ring of pyrazolone markedly elevated the inhibitory effect compared with methyl, and the antimicrobial sequence of R group on the p-position of phenylhydrazine can be generally summarized as: Cl > Br > OMe > OCH2H5.

In 2017, Abdel Reheim and Baker [26] synthesized multiple pyrazolone derivatives and screened the antimicrobial activity, among which compound 29 exhibited strongest antibacterial and antifungal activities, and compound 30 (Fig. 3) showed significant antifungal effect (Table 1). The results of antimicrobial test can be concluded as that the introduction of active substitutions such as pyrano, pyridazine and pyrimidine can promote the antimicrobial activity of the pyrazolone nucleus to different degrees.

Alkhaldi et al. [27] synthesized pyrazolone derivative 31 (Fig. 3) with multiple antimicrobial effects (Table 1). Concerning SAR, meta dichloro phenyl group on the benzene ring of the Schiff base was...
helpful to improve the antibacterial activity, and the subsequent molecular docking of the interactions of 31 within potential target glucosamine-6-phosphate synthase (Fig. 4) provided evidence for the antimicrobial effect of 31, the pyrazolone and the 2,4-dichlorophenyl moiety made the different binding models between 31 and glucosamine 6-phosphate, but the inhibitory potency is significant as well.

Bhattacharjee and colleagues [28] presented pyrazolone compounds 32, 33, 34 and 35 (Fig. 3) which exhibited favorable inhibitory effect against Bacillus cereus with the MIC values of 0.78, 0.78, 0.78 and 0.39 mg/mL, respectively, and suppressed the growth of Klebsiella pneumoniae with the MIC values of 0.78, 0.39, 0.39 and 0.78 mg/mL, respectively. The preliminary SAR extracted from the results was that pyrazolone group was necessary to the antibacterial activity and the 3,4-dimethoxyl group on A ring was the potential effective substituent group.

Another research reported that pyrazolone derivatives 36, 37 and 38 (Fig. 3) were potent compounds with anti-bacterial activity and anti-fungal activity exerted to different degree (Table 3) [29]. In regard to SAR, it was obvious that only compounds 36, 37 and 38 exhibited anti-fungal activity among the analogues, and in the antibacterial evaluation, 36, 37 and 38 were efficient inhibitor of
The author held the point that the antimicrobial effect of pyrazolone derivatives was observed, and the presence of electron-donating groups on the C-3 or the C-4 side of benzene ring could strengthen the activity. SAR indicated that derivatives with pyrazole-1-carbothiohydrazide moieties exhibited higher inhibitory effect than derivatives containing pyrazolyl thiadiazine moiety. Additionally, the presence of free carbothiohydrazide unit enhanced the activity of compounds (Fig. 3).

Ibrahim Ali M. Radini synthesized pyrazolone derivatives 44, 45, 46, and 47 (Fig. 3) as antimicrobial agents (Table 1). SAR indicated that derivatives with pyrazole-1-carbothiohydrazide moiety exhibited higher inhibitory effect than derivatives containing pyrazolyl thiadiazine moiety. Additionally, the presence of free carbothiohydrazide unit enhanced the activity of compounds 44, 45, and 46 and the presence of electron-donating groups (EDGs) at the aromatic ring promoted the inhibitory effect of compound 44.

Bihani and co-workers synthesized zwitterion pyrazolone analogues 47, 48, 49, 50 (Fig. 3) with the antimicrobial properties listed in Table 1, the moderate inhibitory effects against Pseudomonas syringae and Proteus vulgaris were also reported. SAR can be inferred that electrophilic substituted groups on the C-3 or C-4 side of benzene ring could strengthen the activity.

Oraby and teammates synthesized 2,4-disubstituted phenylhydrazonopyrazolone and isoazolone analogues as antibacterial agents. The results of antibacterial test suggested that the compounds contain the scaffold of pyrazolone like 51 and 52 (Fig. 3) exhibited weak antibacterial effect against the multiple resistant strains of clinical isolates.
strains. Interestingly, the inhibitory activity was promoted simultaneously when the pyrazolone moiety was replaced to isoxazolone. Furthermore, docking study indicated that cation-π interactions between isoxazolone analogues and Arg 225, which was a residue played a crucial role in the stabilization of the cofactor during the catalysis in flavin adenine dinucleotide, increased the antibacterial effect of isoxazolones. The antibacterial effect of the analogues was influenced by the substitution on C-2 of the phenyl ring, the substitutions with electron withdrawing groups (EWGs) including F and Cl atoms selectivity increased the antibacterial effect against S. aureus compared to bulky moieties such like methyl.

3.1.2. Coordination pyrazolone compounds as antimicrobial agents

Microorganisms acquire metals from the environment and use them for many essential cellular processes [35]. Metals are able to affect bacterial growth, vitality, and survival [36], and effectively removing metals using metal chelators makes bacterial cells more susceptible to a variety of antibacterial agents, causing cell lysis and loss of viability. Chelators, including EDTA (ethylenediaminetetraacetic acid) and metal complexes of chalcone and flavonoids [37,38], have attracting attentions in this field. Recently, many research groups made unremitting efforts to the synthesis and characterization of transition metal chelates of pyrazolones. Pyrazolones were likely to form several types of coordination compounds due to the several electron-rich donor centers [39]. Coordination compounds containing pyrazolone-based ligands are reported to be superior reagents in antimicrobial agents. In 2011, a research about Mn(III) mixed-ligand complexes with bis-pyrazolones and ciprofloxacin drug was published [40], the antimicrobial outcome showed that when added into the strains of microorganisms (E. coli, Serratia marcescens, S. aureus and B. subtilis), the mixed-ligand complexes which contain the moiety of bis-pyrazolones and ciprofloxacin exhibited stronger inhibitory effect compared with bis-pyrazolones, in which compounds 53 and 54 (Fig. 5) were the potential active antimicrobial agents. SAR can be suspected as that the chelation decreased the polarity of the central atom due to partial sharing of its positive charge with the donor moieties and possible electron delocalization over the whole chelation ring. The complex molecule promoted the hydrophobic character of the metal chelate and the liposolubility, hence favoring its permeation through the lipoid layer of the cell membrane of microorganism.

Jadeja and co-workers [41] synthesized multiple pyrazolone-based complexes and evaluated the bioactivity. The consequence indicated that compound 55 (Fig. 5) showed stronger inhibitory effect against B. subtilis than other derivatives, at the dose of 3 mM, compound 55 suppressed the growth of B. subtilis strain with the diameter of inhibition zone of 25 mm.

Schiff bases derivatives of pyrazolone intrigue attention of coordination chemists as versatile spacers due to their viable accessibilities and structural diversity. Joseph et al. [42] prepared two kinds of copper complexes derived from 4-formylpyrazolone (56 and 57, Fig. 5) and tested the antimicrobial activity against multiple strains. The result showed that both compounds 56 and 57 suppressed the growth of stains and the effect were quite comparable

![Fig. 4. Ligand-protein interactions of compound 31 (A) and original ligand (B) with the active site of glucosamine-6-phosphate synthase (PDB ID: 2VF5) accomplished by Discovery Studio 2019.](image)

### Table 3

| Com. | Antimicrobial zone (mm) | Anti-fungal activity |
|------|-------------------------|---------------------|
|      | B. subtilis | S. mutans | M. luteus | P. aeruginosa | S. typhi | S. paratyphi | E. coli | C. albicans | T. viride | A. niger |
| 36   | 18.5       | 29.5       | 18.5      | 14.5        | 19.5     | 19.5    | –        | 15.5       | 13.5     | –       |
| 37   | 19.5       | 18         | 16.5      | 14.5        | 20.5     | 19.5    | –        | 18.5       | 10.5     | –       |
| 38   | 22.5       | 14.5       | 21.5      | 13.5        | 20       | 20      | –        | 28.5       | 21.5     | –       |
| 39   | 18.1       | –          | –         | 17.4        | –        | –       | 15.3     | –          | –        | 15.2  |
| 40   | 25.3       | –          | –         | 19.3        | –        | –       | 23.1     | –          | –        | 25.5  |

![Ligand-protein interactions of compound 31 (A) and original ligand (B) with the active site of glucosamine-6-phosphate synthase (PDB ID: 2VF5) accomplished by Discovery Studio 2019.](image)
to the standard drugs including Levofoxacin and Moxifloxacin, 2,4-dimethyl derivative 56 was more effective than 3,4-difluorol derivative 57.

Lunagariya et al. [43] synthesized several organometallic platinum (II) analogues containing pyrazolone and determined their bioactivities. Among the analogues, compound 58 (Fig. 5) displayed the strongest antimicrobial activities against P. aeruginosa, B. subtilis, S. Aureus, S. marcescens and E. coli with the MIC values of 35 μM, 30 μM, 25 μM, 22 μM, and 32 μM, respectively. SAR research can be recapitulated that inhibitory effect was influenced by introducing different substitutions on A ring. The presence of methoxyl group at 4-position on of A ring exhibited significantly increased antibacterial activity against S. aureus. It can be recapitulated that inhibitory effect was in increasing one with the highest zones of inhibition i.e. 10.5, 14.3 and 32 mm measured in P. aeruginosa, S. aureus and E. coli. SAR for the analogues can be summarized that replacement on the indole ring exhibited further significant increase against VEGFR-2 especially at the position of C-4 on the ring.

Inspired from existing VEGFR-2 inhibitors, the same research group [50] modified the structure 61 by introducing a 4-benzoyloxy substituent to generate compound 62. Further investigation on structural modifications of the aromatic moiety of 62 revealed that compound 63 (Fig. 6) was the most promising anaplastic lymphoma kinase (ALK) inhibitor (IC50: 5 nM). As for SAR, it was demonstrated that a plenty of halogen substituent groups on the aromatic ring were favored for ALK inhibitory potency. Moreover, the authors paid attention to the modification of the heterocyclic moiety and SAR analysis was concluded that compound bearing amine moiety with longer polar side chains or with hydrophilic moiety could improve inhibitory activity.

3.2. Antitumor agents

In the 21st century, malignant tumor is one of the leading causes of death and developing new antitumor agents with less drug resistance and side effects needs to be done as soon as possible [45]. In recent years, pyrazolone derivatives and their metal complexes have attracted the great attention of researchers for their potential antitumor activity and their less drug resistance and side effects [46]. So far, diverse pyrazolone analogues with antitumor potency have been reported.

3.2.1. Pyrazolones as antitumor agents and their SAR

3.2.1.1. VEGFR-2 target inhibitors. Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2), also known as Flk-1, is mainly expressed in vascular endothelial cells and hematopoietic stem cells [47]. It is highly expressed in a variety of malignant tumors and plays a significant regulatory role in the metastasis and angiogenesis of tumor. Taking VEGFR-2 as the target, the search for VEGFR-2 inhibitors provides a good way to find some new anticancer drugs. Based on conserved active binding sites of VEGFR-2 and similar interaction conformation with ligands, several novel inhibitors of VEGFR-2 have been developed [48], in which pyrazolones play important roles as well.

In 2006, Tripathy and co-workers [49] synthesized a train of heterocyclic-substituted pyrazolones and tested inhibitory potency against VEGFR-2 kinase, among which compound 60 (Fig. 6) was proved to be the most potential derivative inhibiting VEGFR2 kinase with the IC50 value of 6 nM. SAR for the analogues can be summarized that replacement on the indole ring exhibited further potency increase against VEGFR-2 especially at the position of C-4 on the ring.

Gu et al. [51] prepared a series of novel pyridine analogues bearing pyrazolone skeleton and evaluated the cell proliferation activities of synthetic analogues. Among all compounds, 64, 65 and 66 (Fig. 6) exhibited favorable inhibitory potential on c-Met and VEGFR-2. The most promising analogue 66 significantly inhibited the targets c-Met (IC50: 0.11 μM) and VEGFR-2 (IC50: 0.19 μM) kinases in vitro. SAR analyses suggested that substitution of pyridine amine moiety with longer polar side chains or with hydrophilic group could improve inhibitory activity.
3.2.1.2. c-Met target inhibitors. Receptor tyrosine kinase c-mesenchymal epithelial transition factor (c-Met), a vital target in antitumor therapy, plays a crucial role in the occurrence, development, metastasis and angiogenesis of tumors. In 2012, according to the theory of Structure-Based Drug Design, Norman and co-workers [52] designed and synthesized a series of class II c-Met inhibitors, among which derivative 67 (Fig. 6) was confirmed to possess excellent potency against c-Met (Ki: 1.0 nM). This privilege compound was demonstrated to show binding affinity not only with c-Met (PDB ID: 3U6H) (Fig. 7A), but also with VEGFR-2 kinase (PDB ID: 3U6J) (Fig. 7B) with the help of X-ray analysis of cocrystals. Obviously, the pyrazolone moiety plays crucial roles in occupying active sites of binding pocket, forming the pi-alkyl with Val 1155 in c-Met and H-bond with Asp 1046 in VEGFR-2 kinase, suggesting the broad prospect of pyrazolones developing as antitumor agents in the future. This study provides a new strategy for designing more selective analogues. Therefore, Liu et al. [53] synthesized a cluster of pyrazolone-based analogues according to compound 67 and screened the most selective class II c-Met inhibitor. Among them, compound 68 (Fig. 6) was the representative active antitumor agent. SAR investigation revealed that the 6-methoxy group of quinoline in the region (A), the pyridine in the central ring (B) and 2-hydroxypropyl side chain at N-1 could promote the selectivity and activity. In addition, the polar functionality at C-5 position of the pyrazolone was important for selectivity.

A potential compound 69 (Fig. 6) was designed and synthesized by Zhou and colleagues [54], inspired from the structure of abozantinib and foretinib as c-Met inhibitor (IC50: 2.20 nM) to show antiproliferative effect against multiple cancer cell lines, respectively. SAR investigation could be concluded that substitution of the
tory activities against SIRT1 with IC50 values of 41 μM and 27 μM, respectively. In addition, compound 70 displayed the most promising inhibitory effect against SIRT3 (IC50: 6 μM). According to the pharmacophore investigations, SAR can be sum up as the presence of pyrazolone ring was important to improve the inhibitory effect on SIRT1 and SIRT3 through maintaining the balance of H-bond donor and acceptor moieties, from the active analogue.

3.2.1.3. Other antitumor pyrazolone derivatives. Human SIRTs (Sirtuins) are relative to cell senescence, apoptosis, metabolism, proliferation and differentiation. In the past decade, they have emerged as targets for cancer chemotherapy. SIRT1, SIRT2 and SIRT3 are relatively important in the SIRTs family with extensive research. Mahajan and teammates [55] prepared a multiple of five-membered ring pyrazolone analogues as Sirtuin inhibitors. Among these products, compounds 70 and 71 (Fig. 6) showed the inhibitory activities against SIRT1 with IC50 values of 41 μM and 27 μM, respectively. In addition, compound 70 displayed the most promising inhibitory effect against SIRT3 (IC50: 6 μM). According to the pharmacophore investigations, SAR can be sum up as the presence of pyrazolone ring was important to improve the inhibitory effect on SIRT1 and SIRT3 through maintaining the balance of H-bond donor and acceptor moieties, from the active analogue 71, the introduction of bulky hydrophobic benzene group at the C-6 position of naphthalene was helpful to increase the activity on SIRT3. Moreover, the selective inhibition on SIRT2 was significantly elevated when the H-bond donor NH group on the position 1 was replaced as H-bond acceptor O.

It’s reported that pyrazolone was potential to be the starting point for generating RalA inhibitors, which were often activated in human cancer cell lines. Derivative 72 (Fig. 6), as the most promising anticancer candidate, was designed and synthesized by Zhang and colleagues [56]. The consequence for ability of compound 72 inducing apoptotic death in PANC-1 cells showed that derivative 72 suppressed RalA according to inducing the accumulation of ROS and trigger mitochondrial apoptosis in PANC-1 cells.

Markovic and colleagues [57] designed and synthesized compound 73 and its 5-phenylpyrazole derivative 74 (Fig. 6) which exhibited the most promising activity (Table 4). QSAR study revealed that geometrical and topological are the most momentous factors for effect of the analogues, for instance, the size and shape of the molecule. Containing planar benzene group at N-1 position of pyrazolone showed superior inhibitory potency on both cells tested for it was a more favorable conformation moiety when interacting with active sites. Herein, the inhibitory effect on the target mostly depended on fragment at the C-4 position through forming H-bonds with active place.

Pyrazolone derivatives such as 4-aminoantipyrine are well known compound used widely prophylactic of some diseases including cancer. Ghorab and colleagues [58] synthesized a variety of pyrazolone derivatives 75–81 (Fig. 6) inspired from 4-aminoantipyrine and determined the anticancer activity (Table 4). SAR study can be summarized that the most potent compound belonged to the pyrimidine derivatives especially the halogen group.

Dube and colleagues [59] synthesized a cluster of pyrazolone heterocyclic derivatives and evaluated their cytotoxic activities in vitro. The results of brine shrimp lethality assay showed that compound 82 displayed a favorable cytotoxic activity than standard cyclophosphamide. In addition, compounds 82 and 83 (Fig. 6) were found to be prominent analogues with the lethality concentration (LC50) values being 10.8 μg/mL and 14.5 μg/mL in sulfonamide B (SRB) assay, respectively. SAR investigation implied that the dimethoxy substitution on ring A increased the antitumor activities, the group of hydrophobicity and hydrophilicity played a significant role in cytotoxic activities.

Gouda et al. [60] prepared several pyrazole analogues and tested the cytotoxicity against the Ehrlich ascites carcinoma cells (EAC). To detail, the cytotoxicity data clearly displayed that and compounds
84 and 85 exhibited favorable activities compared with 5-fluorouracil (Table 5). SAR can be recapitulated that introducing a hydrazopyrazol-5-one ring in position 2 to benzothiophene was important to the cytotoxic activity, furthermore, the order of antitumor activities of compound follows $86 < 87 < 88$ and $84 < 89 < 90$ (Fig. 6), it can be speculated that the group of COOH at position 3 of the thiophene ring system in compounds increased the antitumor activity.

3.2.2. Coordination pyrazolone compounds as antitumor agents

In 2013, Vyas and colleagues [61] synthesized the new pyrazolone based complex 91 (Fig. 8) for the first time, which was suggested to be a potent antitumor agent against lung cancer cell lines (A549). According to evaluation of the cytotoxic activities against A549 cell lines and noncancerous rat cardiomyocytes (H9C2) cell lines in vitro, the result displayed that compound 92 (Fig. 8) possessed a superior cytotoxic property. Moreover, LDH activity of compound 92 showed the higher levels in the culture medium treated with A549 cells. It was worth mentioning that the chelation of Cu (II) with the pyrazolone and bipyridyl ligands formed the π-π conjugation in which gave the extended planar structure resulting in the superior cytotoxic property.

Zhao and colleagues [62] prepared a cluster of novel mixed-ligand dibutyltin (IV) complex pyrazolone, all of the synthesized complexes were screened against two human cancer cell lines (KB and HeLa) in vitro and utilized MTT assay to evaluate antitumor activity. The results suggested that all complexes display a favorable antiproliferative activity against KB and HeLa cell lines with the IC$_{50}$ values ranging from 0.29 to 0.54 μM for KB and 0.05 – 0.31 μM for HeLa. Compound 93 (Fig. 8) exhibited the most potent activity (IC$_{50}$: 0.05 μM) against HeLa cell. SAR study implied that acetyl from acylpyrazolone and para-fluorobenzoate ligand may play a considerable role for increasing the antitumor activities.

Three kinds of pyrazolone complexes 94–96 (Fig. 8) were synthesized by Bakr and co-workers [63]. The MTT assay outcomes implied that HL exhibited the better cytotoxic activity against HePG2 and PC3 cell lines than 5-Fluorouracil with IC$_{50}$ values being 5.69 and 6.80 μg/mL, respectively (Table 6). For metal complexes, the order of cytotoxicity was found to be 95 > 94 > 96.

Zhang and colleagues [64] synthesized two new transition metal complexes with 4-acylpyrazolone derivative as potential antitumor agents. According to the results of antitumor determination, the complex 97 (Fig. 8) was proved to exhibit higher cytotoxic activity with IC$_{50}$ values being 1.9 μg/mL for human esophageal cancer cells (Eca-109) and 1.2 μg/mL for cervical cancer cells (HeLa). The study suggested that the complex 97 might be an effective agent for tumor.

3.3. CNS agents

Because of the intricate pathogenesis and devastating effects, CNS disease is still a challenge for researchers to find novel precursors as the therapy [65]. In view of the experiment of the development of edaravone, several pyrazolones have been taken into account to be the CNS agents, existing literatures mainly focus on the anticonvulsant, antidepressant, anti-amotrophic lateral sclerosis, anti-Alzheimer’s activities and inhibitory effect against other CNS related targets. Herein, we summarized the bioactivity and SAR for the synthetic derivatives, wishing to give evidence for pyrazolones to develop as CNS clinical agents.

3.3.1. Anticonvulsant agents

Epilepsy is a chronic neurological disorder syndrome identified by the spontaneous recurrence of seizures which can disrupt periods of more or less normal electroencephalographic (EEG) activity and behavior [66]. Currently the anticonvulsant drugs are chiefly derived from benzodiazepines or GABA (γ-aminobutyric acid) analogues, pyrazolone derivatives are likely to provide a novel orientation for drug design. Eldebs et al. [67] synthesized pyrazolone-based heterocycle compounds as monoamine oxidase (MAO) inhibitors and evaluated the tryptamine seizure potentiation in rats. The results manifested that compounds 97 and 98 (Fig. 9) were the most promising candidates (Table 7).

Viveka et al. [68] prepared pyrazolone analogues 99 and 100 (Fig. 9) with favorable anticonvulsant activities. In the maximal electroshock (MES) test, compound 99 performed the best protective potency with the protection ratio of 79.76% and no significant toxicity was determined at the dosage of 25 mg/kg, while in the analgesic test it showed weak effect. Compound 100 exhibited moderate protection on the reaction time of mice. SAR study demonstrated that the existing of pyrazolone moiety elevates the

### Table 5

| Com. | % Apoptosis |
|------|-------------|
|      | 100 μg/mL   | 500 μg/mL | 25 μg/mL |
| 5-Fluorouracil | 97.3% | 68% | 38.6% |
| 84 | 84% | 53.3% | 29.8% |
| 86 | 100% | 98.6% | 94% |
| 87 | 98.4% | 81% | 65% |
| 88 | 98.1% | 72% | 60% |
| 89 | 96.5% | 66.6% | 38.1% |
| 90 | 79.4% | 71% | 43% |

### Table 6

In vitro cytotoxicity of compounds 94–96 towards the cell lines.

| Com. | In vitro cytotoxicity IC$_{50}$ (μg/mL) |
|------|---------------------------------------|
|       | HePG2 | HCT-116 | PC3 | MCF-7 |
| 5-Fu  | 7.9 | 5.2 | 8.3 | 5.5 |
| 94    | 15.31 | 16.93 | 17.30 | 27.47 |
| 95    | 10.73 | 14.65 | 11.45 | 12.96 |
| 96    | 28.30 | 20.59 | 20.40 | 35.62 |

![Fig. 8. Coordination pyrazolone compounds as antitumor agents.](image)
anticonvulsant potency. As for the analgesic effect di-Cl substituent group on the heterocyclic systems promoted the activity, whereas slightly less activity was determined for the analogues with di-F substituents.

A cluster of pyrazolone analogues were synthesized and assessed for the anticonvulsant and antidepressant activities by Abdel-Aziz and colleagues [69]. Compounds 101, 102 and 103 (Fig. 9) displayed the most potent protective potency against pentylenetetrazole (PTZ)-induced clonic seizures in mice at a dosage level of 20 mg/kg with the protective ratio for 74.5, 78.7 and 74%, respectively, which was close to phenobarbital sodium (30 mg/kg) and better than phenytoin sodium (30 mg/kg). Preliminary SAR study can be concluded that the existence of cricoid pyrazolone group increased the anticonvulsant effect compared with the linear Table 7

| Com. | Kᵢ (nM) MAO-A | Kᵢ (nM) MAO-B | SI$^a$ | MAO-A IC₅₀ (nM) | MAO-B IC₅₀ (nM) | ED₅₀ (µM) in vivo |
|------|---------------|---------------|--------|-----------------|-----------------|------------------|
| Deprenyl | – | – | – | 3.90 × 10⁻⁶ | 3.00 × 10⁻⁸ | 0.30 |
| 97   | 0.014  | 121.34         | 8667.143 | 2.34 × 10⁻⁶ | 13.23 × 10⁻⁶ | 19.23 |
| 98   | 0.346  | 765.87         | 2213.497 | 7.99 × 10⁻⁶ | 45.43 × 10⁻⁶ | 47.54 |

$^a$ SI (selectivity index) = Kᵢ (MAO-B)/Kᵢ (MAO-A) ratio.

Fig. 9. Pyrazolones as CNS agents.
3.3.2. Antidepressant agents

Meruguonolu and co-workers [70] prepared multiple pyrazolone derivatives and estimated the anti-depressant effect in vivo. The consequence demonstrated that the most promising derivatives 104 and 105 (Fig. 9) possessed remarkable anti-depressant activity in forced swimming test and tail suspension test (Table 8), with the relative values in the same magnitude of imipramine. As for SAR, the substituted groups on the 3,4-position of the ring of aromatic hydrazine exhibited better activity than other substituted groups.

3.3.3. Anti-amyotrophic lateral sclerosis agents

The pyrazolone skeleton is an effective group characterized in a cell-based high throughput screening assay targeting mutant Cu/Zn superoxide dismutase 1 (SOD1) induced toxicity and aggregation as a marker for amyotrophic lateral sclerosis (ALS), which is an orphan neurodegenerative disease so for without a cure with the incidence of 1–2 per 100000 per year and 2–5 years from diagnosis to death [71,72].

A cluster of pyrazolone analogues were screened and evaluated for the anti-ALS activity from FDA approved drugs and biochemical reagents by Radhia and co-workers [73], as the most potent skeleton, the arylsulfonyl pyrazolones showed 100% efficacy compared with the positive control, radicicol (80% efficacy) in the test of G93A-SOD1 expression in PC12 cells model. CMB-003299 (106, Fig. 9) was the typical compound to decrease the mutant SOD1 aggregation with the ED50 value of 400 nM, and the weak cytotoxic effect was detected with the LD50 > 100 μM.

In the sequent research, a series of ether analogues with more metabolically stability were synthesized [74]. The most effective derivative 107 (CMB-087229) (Fig. 9) showed superior potency and in vitro pharmacological and pharmacokinetic features including protection against the mutant SOD1-induced cytotoxicity (ED50: 67 nM), good performance in the evaluation of potassium channel blockages, the potency of analogues reduced in the sequence: Cl > F > Br > Ph.

3.3.4. Anti-Alzheimer’s agents

Based on the structure of leading compound edaravone, Tok and co-workers [75] synthesized a cluster of analogues and investigated the potential anti-Alzheimer activity. Among the analogues, compounds 108 and 109 (Fig. 9) exerted most potent inhibitory effects, with the detail data listed in Table 9. For the instance of the most potent AChE inhibiting agent 108 and MAO-B inhibiting agent 109, the initial SAR could be summarized as that the variation of substituent groups strongly affected the inhibitory potency of analogues. Basic nitrogen atom in substituent groups of 108 significantly promoted the AChE inhibitory activity. In addition, incorporation of EWG increased the MAO-B inhibitory activity of 109. It can be seen from the docking analysis that compound 108 was prepared with similar size with donepezil (Fig. 10), and the room of cyclopropene ring can be occupied by pyrazolone ring, providing the evidence of the activity and the idea to capture Alzheimer disease.

| Com. | Forced swimming test | Tail suspension test |
|------|----------------------|----------------------|
|      | Duration of immobility (s) | Change in immobility (%) | Duration of immobility (s) | Change in immobility (%) |
| Control | 203.3 | – | 185.8 | – |
| Imipramine | 94.0 | –53.8 | 109.0 | –41.3 |
| 104 | 97.7 | –51.9 | 114.3 | –38.4 |
| 105 | 129.5 | –36.3 | 111.0 | –40.2 |
According to the structure of (S)-α-aminoadipic acid, which was an activating agent of important functional excitatory amino acid receptor mGlu2 and mGlu6 subtypes, compounds 117 and 118 (Fig. 9) were synthesized by Zimmermann et al. [85] thought some reactions. However, no significant agonist or antagonist activity from test compounds at the mGlu1a, mGlu2, mGlu4a, or mGlu6 subtypes were observed at the dose of 1 mM, the inappropriate pKa of analogues was considered as the potential reason of obstruct interaction of substituted groups with appropriate sites at the receptors.

3.4. Anti-inflammatory agents

More than 100 years of synthetic work have resulted in three privileged pyrazolones derivatives with anti-inflammatory potency, namely antipyrine, propyphenazone and metamizole which are still widely used [86]. The structure characteristic that methyl groups attach to the ring nitrogen atoms to enhance the activity has been retained from antipyrine to newly reported analogues. Based on the structure of marketed anti-inflammatory drugs including antipyrine and aminophenazone, several pyrazolones derivatives have been designed and synthesized as anti-inflammatory agents.

With the thorough understand of inflammatory reactions, using single mice or rat model to evaluate the analgesic effect gradually fall short of demand to investigate the activity, more and more targets are involved into the determination including COX-1, COX-2, 5-LOX, TNF-α, etc. Pyrazolones with anti-inflammatory effects tend to inhibited the activities of COXs and LOXs, which catalyze the conversion of arachidonic acid into prostaglandins or leukotrienes, meanwhile, phosphatase inhibitory of pyrazolones have also been disclosed [87], indicating the potential of pyrazolone motif in this field. The structural similarity between pyrazolone and COX-2 selective inhibitor celecoxib also provides possibility to develop them into potential clinical candidates [88–91]. The gastrointestinal side effects existing in the usage of COX-1 inhibitors and the cardiovascular side effects in COX-2 inhibitors suggest researchers to consider the inhibitory potency of anti-inflammatory agents on both COX-1 and COX-2, the story of the development of imrecoxib and the conception of moderate selectivity for COX-2 enzyme have been reported as references [19]. It can be seen from the binding affinity models of celecoxib and pyrazolone derivative 131 with COX-1 and COX-2 (Fig. 12) that pyrazolone group maintain the similar pi-alkyl effect with electron group of alkyl groups in the pocket residues compared to pyrazole ring because of its property similar to aromatic ring. The carbonyl group in pyrazole is a favorable hydrogen acceptor which is feasible to form potential H-bond with alkaline amino acids like arginine, lysine and histidine, meanwhile, the amino group is a hydrogen donor easy to form hydrogen bond with residues like glutamine (Fig. 12D).

A cluster of pyrazolone and amino pyrimidine derivatives 119–124 (Fig. 11) were synthesized by Antre and co-workers [92], with obvious anti-inflammatory potency in carrageenan-induced rat paw edema model (Table 10). In regard to SAR, in contrast to the substitution of chlorine and nitro, the anti-inflammatory effects of these analogues were significantly promoted when the electron-donating groups of C-6 aminopyrimidine benzene ring were hydroxyl, methoxy and dimethylamine.

Nadia and colleagues [93] synthesized multiple pyrazolone-pyridazine conjugates and screened their anti-inflammatory activity in vivo and in vitro. Compound 125 (Fig. 11) exhibited the strongest anti-inflammatory activity in the test of carrageenan-induced mice paw edema model and in COX-1 and COX-2 inhibition test (Table 10). It also inhibited the production of inflammatory cytokines including TNF-α and IL-6 in serum. SAR study showed that the replacement with bulky aliphatic secondary amines such as morpholine exerted good anti-inflammatory effects.

Mannich base derivatives 126 and 127 (0.03 mmol/kg) (Fig. 11) displayed the remarkable anti-inflammatory effect on the carrageenan-induced acute albino rats paw edema model with inhibitory rates of 77.88% and 79.91%, respectively, after 6 h of administration [94]. The preliminary SAR demonstrated that analogues containing EWGs in the Mannich base phenyl ring at position 4, especially sulfonic group enhanced the activity.

Abbady and co-workers synthesized some new pyridines, pyrans, and indazoles with pyrazoline ring [95]. Among the synthetic products, indazole derivatives 128 and 129 (10 mg/kg) (Fig. 11) obviously suppressed swelling of in rat hind paws induced 5 h after injection of carrageenan, with inflammatory inhibition rates of 56.20% and 55.20%, respectively, indicating excellent anti-inflammatory activity.

A series of 5-methyl-2-phenyl-1H-pyrazol-3-(2H)-one analogues were prepared and determined for their anti-inflammatory effects [86]. The outcome showed that the derivatives 130 and 131 (Fig. 11) were proved to have superior inhibitory potency against both the targets of inflammation COX-1 and COX-2 (Table 10). Furthermore, derivatives 130 and 131 also exhibited favorable anti-inflammatory effect in carrageenan induced rats paw edema model with ED50 values of 102 and 109 mg/kg in vivo, respectively. Regarding SAR, pyrazolones containing C-3 methyl group, C-4 urea substitution and carbonyl at 5-position posed an impact on COX
enzymes inhibition. The substituent with urea-phenyl group at 3-phenyl ring was more active than that containing chlorine at the same position and unsubstituted urea. Moreover, thiourea derivatives imparted strengthen activity compared with those with urea and guanidine.

Ashraf et al. [97] successfully prepared two series of pyrazolone analogues and tested their anti-inflammatory effect in vivo and in vitro. The derivative 132 and the enolate 133 (Fig. 11) displayed excellent inhibitory activity on COX-2 (Table 10) as well as potent edema inhibition. SAR investigation showed that these compounds with unsaturated moiety such as the allyl and aryl groups maintained stronger activities than those with alkyl groups. Thiourea analogues 132 also improved anti-inflammatory potency in the presence of the bulky hydrophobic cyclohexyl group.

El Sayed and colleagues designed and synthesized novel heterocyclic derivatives containing antipyrine and pyrazolone framework [98]. The pharmacology tests result revealed that derivatives 134–136 (Fig. 11) exhibited significant anti-inflammatory activities in different degree both in vivo and in vitro (Table 10). The SAR study indicated that the presence of the 3-benzo[d] [1,3]dioxole ring system and the N-containing heterocyclic amine attached to the methyl group at 4-position of the antipyrine structure was very essential for activity as in case of compounds 134 and 135.

A cluster of novel pyrazolone analogues containing amino-sulfonyl group were synthesized and investigated for the anti-inflammatory potency [99]. The outcome showed that three compounds 137–139 (Fig. 11), as potent anti-inflammatory agents, exerted strong inhibitory effects against both COX-2 (Table 10) and 5-LOX (IC50: 0.53, 0.52 and 0.57 μM in order) with superior COX-2 SI values. Compounds 138 and 140 remarkably diminished rat paw edema induced by carrageenan with ED50 values of 0.044 and 0.079 mmol/kg, respectively, exhibiting excellent anti-inflammatory activity in vivo. In terms of SAR study, the replacement of 2-carbonyl group in the derivatives with SO2NH2 as the main active group promoted activity.

Fahmy et al. [100] tested anti-inflammatory effects of several novel O-substituted salicylamides. Among all analogues, pyrazolone derivative 141 (Fig. 11) exhibited moderate anti-inflammatory activity in carrageenan-induced edema model. The multiple bioactivity test results indicated the pyrazolone and the structurally similar group pyrazole could be the potential substitutions.

Golebiowski and co-workers synthesized some novel monocyclic pyrazolone and investigated their inhibition on the inflammatory cytokines [101]. The outcome showed that compound 142 (Fig. 11) significantly reduced the expression of TNF-α induced by lipopolysaccharide (LPS) with IC50 value of 13 nM. Furthermore, through SAR study, it can be found that benzyl amino substituents were more active than those of aminopyridine ring, and N-methyl substitution on the pyrazolone was more effective than ethyl

Fig. 11. Pyrazolone derivatives with anti-inflammatory activity.
Fig. 12. Ligand-protein interactions of celecoxib (A) and pyrazolone derivative 131 (B) with the active site of COX-1 (PDB ID: 3KK6), celecoxib (C) and pyrazolone derivative 131 (D) with the active site of COX-2 (PDB ID: SLN1) accomplished by Discovery Studio 2019.

### Table 10
Result of anti-inflammatory activity of the tested derivatives.

| Com. | IC₅₀ (µM) | Selectivity index (SI) | Anti-inflammatory activity (% inhibition) |
|------|-----------|------------------------|----------------------------------------|
|      | COX-1     | COX-2                  |                                        |
| 119  | –         | –                      | –                                      |
| 120  | –         | –                      | –                                      |
| 121  | –         | –                      | –                                      |
| 122  | –         | –                      | –                                      |
| 123  | –         | –                      | –                                      |
| 124  | –         | –                      | –                                      |
| 125  | 2.86      | 0.39                   | 7.36                                   |
| 126  | –         | –                      | –                                      |
| 127  | –         | –                      | –                                      |
| 128  | –         | –                      | –                                      |
| 129  | –         | –                      | –                                      |
| 130  | 80        | 0.20                   | 400                                    |
| 131  | >100      | 1.00                   | >100                                   |
| 132  | 13.40 × 10⁻⁵ | 2.83 × 10⁻⁵         | 4.73                                   |
| 133  | 22.72 × 10⁻⁵ | 4.69 × 10⁻⁵         | 4.84                                   |
| 134  | 1.60      | –                      | 80.00                                  |
| 135  | 1.57      | –                      | 98.00                                  |
| 136  | 1.74      | 0.99                   | 89.20                                  |
| 137  | 4.08      | 0.77                   | 52.9                                   |
| 138  | 3.81      | 0.72                   | 52.9                                   |
| 139  | 3.76      | 0.66                   | 56.9                                   |
| 140  | –         | –                      | –                                      |

Z. Zhao et al. / European Journal of Medicinal Chemistry 186 (2020) 111893
substitution. Currently, the topic of inflammatory reaction has beyond the analgesic agents, immunoreactivity targets also involved. The author observed the interactions of p38 kinase with other metabolites to be oxidized and caused different diseases due to oxidative stress [102]. Pyrazolones played a role in antioxidant activity, referring to the antioxidant mechanism of edaravone, C=CH double bond formed by the action of tautomerism of carbonyl group on pyrazolone was considered to be important [103]. In the light of the structure motif of 4-aminoantipyrine, Schiff base derivative 144 (Fig. 14) was prepared and determined for the antioxidant activity [104]. The derivative 144 exerted a strong antioxidant effect with IC_{50} value of 31.26 μM. As a non-phenolic antioxidant agent, the antioxidant effect of compound 144 was considered to be relative to the formation of proton free radicals by the C-7 or C-11 methyl groups. The Schiff base pyrazolone analogues were also synthesized by Khan et al. [105], among the products, phenol productions 145–148 (Fig. 14) exhibited significant antioxidant effect in DPPH test with the IC_{50} values of 20.14, 19.12, 17.14, 15.16 μM, respectively, which was even stronger than the standard drug n-propyl gallate (IC_{50}: 30.27 μM). SAR study revealed that double phenol group substituted analogues performed better than other moieties because of the reducibility of phenolic hydroxyl group, and 2,5-diOH substitution was stronger than 2,4-diOH.

Gaffer and co-workers [106] screened the antioxidant activity of a cluster of thiazolyl-pyrazolone derivatives through 2, 2-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) radical cation decolorization assay. Compounds 149 and 150 (Fig. 14) (2 mM) exhibited the strongest antioxidant potency with the inhibition of 88.6% and 85.7%, respectively. Thereinto, compound 149 exhibited better activity than standard inhibitor ascorbic acid (inhibition: 88.20%). SAR investigation was concluded as that the presence of benzene on the thiazole ring and phenylthiocarbamoyl moiety along with core pyrazolone group was benefit to the antioxidant effect. Additionally, 4-phenyl substituent group on the thiazole ring was better than the methyl substitution.

3.6. Anti-tuberculosis agents

Tuberculosis (TB) is an airborne infectious disease caused by Mycobacterium tuberculosis (MTB) and embodies one of the leading causes of death around the world [107]. The dangerous spread of TB is primarily because of its association with HIV infection and to the rapid development of multidrug-resistant (MDR) strains of MTB [108]. Pyrazolone as the precursor has been reported to show potential antitubercular activity.

Sivakumar et al. [109] prepared two series of hybridized pyrazolone analogues and determined their antitubercular effect. The most potent compounds 151 and 152 (Fig. 15) possessed apparent antitubercular effects (IC_{50} < 0.1 μg/mL). Furthermore, SAR investigation indicated that the antitubercular activity of the compounds was markedly improved in the absence of double bond in the imine side chain and the benzene ring at the end of pyrazolone moiety. Petheiaih et al. [110] synthesized several 2-aryl-5-methyl-2,3-dihydro-1H-3-pyrazolone analogues in water through one-pot process and investigated the antitubercular activity against MTB in vitro. The MIC value of potential compound 153 (Table 11) (Fig. 15) was better than clinical drugs. SAR showed that the replacement on the N-aryl ring of derivatives contributed antimycobacterial activity. Specifically, the analogues containing electron-withdrawing groups with halogens and nitro groups showed stronger activity compare with aryl rings containing electron-donating groups such as methoxide, methyl and isopropyl.

Daniele et al. [111] prepared various pyrazole analogues and evaluated their antitubercular activities against M. tuberculosis. Compound 154 (Fig. 15) was the most potent candidate (Table 11). SAR study demonstrated that the halogens on phenyl ring and the methyl group at third position of pyrazole ring showed higher antitubercular effect than that contained alky in the same position.

Two series of new pyrazolone analogues were prepared and assessed for the anti-MTB activity [112]. Two analogues 155 and 156 (Fig. 15), containing the p-chlorophenyl ring, were regarded as the most promising MTB inhibitors (Table 11). Meanwhile, the presence of N-methyl-piperazine and morpholine groups remarkably improved anti-MTB effects.

Several Mannich bases and Schiff bases of pyrazolone framework were synthesized [113]. The results showed that analogue 157 (Fig. 15) could be used as a potential antitubercular drug due to its extremely high activity (Table 11) over that of the standards ethambutol and ciprofloxacin. SAR study revealed that derivatives with acyl substituent had better anti-MTB ability than those comprising EWGs such as nitro, chlorine, and carboxyl and electron donating group including hydroxyl.

Ahsan and co-workers [114] designed some diversified pyrazolone derivatives aiming at MTB and isoniazid resistant MTB, among which compounds 158 and 159 (Fig. 15) exhibited pronounced inhibitory effect (Table 11), the outstanding inhibitory effect of 159 against isoniazid resistant MTB strain was observed as well and the compound 158 was revealed to show strong antibacterial effect simultaneously. SAR study revealed that N-aryl with electronnegative substituent group showed strongest antitubercular potency, in which 4-pyridinyl group had maximum inhibition, compared to 2-chlorophenyl, 4-chlorophenyl and 4-aminophenyl group substitution. The electron donating group such as 4-
methoxyphenyl, 2-methylphenyl, 3-methylphenyl and 4-methylphenyl exhibited less inhibition. In the follow up research [115], the potent compound 160 (Fig. 15) was selected from the novel synthesized analogues with excellent activity and free from cytotoxicity (>62.5 μg/mL) appeared. Better drug-likeness was obtained after adding the imine group between the oxadiazol and the phenyl ring and SAR was summarized as that EWGs produced more inhibitory effect.

3.7. Antiviral agents

Multiple viruses widely exist in the nature and threaten public health [116]. Pyrazolone has been used to generate antiviral agents, involving in anti-orthopoxvirus, anti-protease-resistant prion protein (PrP-res), anti-severe acute respiratory syndrome (SARS) and anti-buffalopox virus (BPXV) agents.

Fan et al. [117] synthesized a series of pyrimidine-pyrazolone nucleoside chimera analogues and determined the anti-orthopoxvirus activity in vitro. The consequence proved that compounds 161 and 162 (Fig. 16) exerted the most potent anti-orthopoxvirus effect (Table 12). SAR study revealed that the activity was enhanced after matching with the pyrazolone moiety.

In 2007, Kimata and co-workers [118] reported the synthesis and assessment of multiple PrP-res accumulation inhibitors according to the structure of edaravone, in which the most potent compound 163 (Fig. 16) displayed PrP-res inhibitory effect in the ScN2a cells with IC50 value of 3 nM, which was 130 times more active than quinacrine and more than 300-fold effective than edaravone. Furthermore, no significant SOD (superoxide dismutase)-like activity was observed, indicating potential novel mechanism of the PrP-res inhibitory effect. SAR study demonstrated that the position and class of substitutions were not directly related to the potency of suppressing the accumulation of PrP-res but substituted the nucleus with 1-cyclohexyl, 3-isopropenyl, 3-(4-nitrophenyl) and 4-benzoyl could enhance the inhibitory activity.

Srinivasan and teammates [119] synthesized several spiro-piperidinyl pyrazolone derivatives inspired from the skeleton of

![Fig. 14. Antioxidant of pyrazolone derivatives.](image)

![Fig. 15. Pyrazolones with antitubercular activity.](image)

| Com. | MTB MIC (μg/mL) | IC50 (μM) | Selectivity index (SI) |
|------|----------------|----------|-----------------------|
| 151  | –              | <0.37    | 633.35                |
| 152  | –              | <0.44    | 630.75                |
| 153  | 0.79           | –        | –                     |
| 154  | 4.00           | –        | –                     |
| 155  | 4.00           | –        | –                     |
| 156  | 4.00           | –        | –                     |
| 157  | 3.11           | –        | 26.35                 |
| 158  | 1.97           | –        | –                     |
| 159  | 0.78           | –        | –                     |
| 160  | 0.78           | –        | –                     |
spiramide and assessed their antiviral properties against *Buffalopox* caused by BPXV on Vero cells *in vitro*. The results suggested that derivatives 164, 165, and 166 (Fig. 16) were the most potent analogues with electron donating groups on the aromatic ring.

Kumar and coworkers [120] synthesized multiple pyrazolone analogues as SARS-coronavirus (CoV) and Middle East Respiratory Syndrome (MERS)-CoV 3C-like protease inhibitors, among which compounds 167 and 168 (Fig. 16) exerted the strongest inhibitory effects against SARS and MERS with IC₅₀ values of 6.4 and 5.8 μM (167), 5.8 and 7.4 μM (168), respectively. SAR study revealed that the carboxylate group is a crucial pharmacophore and its presence either at the C-2 position of ring A or moiety B is critical for the activity, meanwhile, the chlorine at C-5 position of ring A slightly decreases the activity. It can be seen from the docking studies that pyrazolone group in both compounds 167 and 168 played important roles to form H-bonds with residues Glu 166 and His 41 in SARS 3CLpro, respectively.

### 3.8. Lipid-lowering agents

With the change of people’s lifestyle and dietary structure, the incidence of fatty liver is increasingly high. In particular, non-alcoholic fatty liver disease (NAFLD) has seriously endangered people’s life and health [121]. However, due to the complex pathogenesis [122], it is often neglected in clinical practice. Pyrazolinone derivatives can reduce cholesterol and lipid accumulation in the body by regulating multiple indicators, such as AMPK and FXR. Therefore, it is of importance to improve the lipid-lowering activity by modifying the structure of pyrazolone. The pyrazolone derivatives are also reported to be the selective antagonists to the nonsteroidal farnesoid X receptor (FXR) [123], which maintains the bile acid homeostasis and plays crucial roles in the control of cholesterol, lipid, and glucose metabolism [124,125]. Based on the screen of the known FXR modulators, the lead compound 169 (IC₅₀: 69.01 μM) was identified with the help of homogeneous time-resolved fluorescence (HTRF) assay. On the basis of 169, further modification was carried out accordingly. The most promising compound 170 (IC₅₀: 8.96 μM) displayed antagonistic capability 10-fold and 8-fold higher than that of the control Z-guggulsterone and the original analogue 169, respectively. Compound 170 was further proved to interact with FXRαLBD with high binding affinity, and potent antagonistic activity against FXR in two cell testing platforms. In addition, compound 170 strongly inhibited the regulating activities of chenodeoxycholic acid on FXR target genes. Furthermore, compound 170 was proved to play a role in lowering the contents of triglyceride and cholesterol in human

### Table 12

Inhibition of orthopoxvirus replication by pyrazolo-pyrimidine nucleosides.

| Com. | EC₅₀ (μM) | Toxicity CC₅₀ (μM) | Neutral red uptake |
|------|-----------|--------------------|--------------------|
|      | Vaccinia CPE | Vaccinia PR | Cowpox CPE | Cowpox PR |
| Cidofovir | 3.2 | 20 | 7.1 | 32 | >317 |
| 161 | 1.7 | 6.9 | 0.3 | 5.6 | >286 |
| 162 | 20 | 11 | 1.8 | 9.0 | >292 |

Note: CPE-reduce viral cytopathogenicity, PR-plaque formation.

*Fig. 16. Antiviral of pyrazolone analogues.*

![Diagram of pyrazolone analogues](https://example.com/diagram.png)
hepatoma HepG2 cells and in the cholesterol-fed C57BL/6 mice. SAR can be interpreted that changes of substituents on the 1, 3, and 4-positions of pyrazolone group had crucial influence on antagonistic effect, and appropriate structural optimizations on the above regions can substantially strengthen activity.

NAFLD is a clinical syndrome identified by hepatic steatosis. It is closely linked to obesity, insulin resistance and dyslipidemia. AMP-activated protein kinase (AMPK) functions as an energy sensor and plays an important role in regulating lipid metabolism [126,127]. According to the structure of lead compound 171 (Fig. 17), Zhang et al. [128] synthesized multiple pyrazolone derivatives as AMPK activators to suppress lipid synthesis and reduce lipid accumulation in ob/ob mice. The most potent compound 172 directly activated the kinase domain of AMPK with an EC50 value of 2.1 ± 0.2 μmol/L and acted as a non-selective activator of AMPK complexes, additionally, compound 172 suppressed the accumulation of triglyceride in HepG2 cells dose-dependently. The outcome demonstrated that the AMPK activators could be part of a treating method for NAFLD and related metabolic disorders.

3.9. Antihyperglycemic agents

Diabetes is considered to be relative to overindulgent life-style and thus is thought as major health concern in industrialized countries [129]. Pyrazolones have been disclosed to be antihyperglycemic through multiple targets including aldose reductase (AR), α-glucosidase and α-amylase. The antihyperglycemic activity of pyrazolone derivatives was explored by Kees et al. [130] The potent compound 173 (100 mg/kg) (Fig. 18) caused a 68% decrease in plasma glucose in db/db mice, moreover, it essentially normalized the level of glucose at 20 mg/kg (57% reduction) and maintained remarkable reduction at 2 mg/kg (30% decrease). SAR could be concluded that the substitution of 4-methylthio, methylsulfinyl, or ethyl to a benzyl group at C-4, in combination with trifluoromethyl at C-4 position of pyrazolone (hydroxy tautomer) formed potent antihyperglycemic agents in mice. In addition, the chemical “trapping” of four of the seven possible tautomeric forms of the heterocycle by mono- and dialkylation at the acidic hydrogens gave several additional potent analogues.

Kadam and co-workers [129] synthesized several pyrazolone derivatives as inhibitors of AR, in which compound 174 (Fig. 18) displayed the most promising inhibitory with IC50 value of 6.30 μM. In regard to SAR, it was possible to note that the hydrophobic groups like benzene ring with pyrazolone adversely influenced AR inhibition, while the introduction of carbothioamide group increased inhibitory effect. Because of the simultaneous existing of arbothioamide moiety and 3-(4I-methoxyphenyl)-1-phenyl-1H-pyrazole and 3-(4I-chlorophenyl)-1-phenyl-1H-pyrazole substituent group at first position of pyrazolone, compound 174 exerted the best activity. Docking analysis suggested that substituted groups of 174 gave the proper placement of hydrophobic groups in respective binding pockets of AR, avoiding the poor interactions because the size of substitutions was too small to occupy the binding pocket, and the pyrazolone moiety in compound 174 was considered to play a role in form H-bond with the residue Cys 298.

Eldebss and colleagues [131] prepared a series of pyrazolones acting as α-glucosidase and α-amylase inhibitors, among which compound 175 (Fig. 18) exerted the most significant inhibitory effects with IC50 values of 14.67 and 63.66 μM, respectively. In the acute diabetic mice model, compound 175 reduced serum glucose level for the ratio of 32.16%, and in subacute study the ratio was 13.34% after administration for 2 h, which was even better than the effect of pioglitazone. The docking analysis indicated that the 1,5-dimethyl group of pyrazolone was important for the interaction between compound 175 and α-glucosidase, additionally, preserving the sulphone group was momentous to the inhibitory effect.

In 2014, Shetty et al. [132] synthesized multiple pyrazolone derivatives as α-amylase inhibitors. The consequence showed that...
compound 176 (Fig. 18) displayed the strongest inhibitory effect with the ratio of 61.6%. The primary SAR can be suspected as that introduction of disubstituted halogen analogues promoted the inhibitory effect due to its high electronegativity, moreover, multifluoro substitution on A ring could be the potential active group.

3.10. Protein inhibitors

In addition to the activities mentioned above, pyrazolones have been shown to inhibit the proteins including K<sub>ATP</sub> channel protein, phosphodiesterase (PDE), aromatase, divalent metal transporter 1 (DMT1), human carboxylesterase1 (hCE1) and transforming growth factor (TGF) βRI, indicating the multiple targets therapeutic action and favorable drug-likeness of pyrazolone derivatives. Drizin and co-workers [133] designed and synthesized a cluster of pyrazolone derivatives as K<sub>ATP</sub> channel openers inspired from disclosed compounds (the skeleton of 177 and 178, Fig. 19), together with the investigation of SAR. It can be concluded that cyclopentanone in the left hand portion (A area) of the derivative was 4-fold more potent than cyclohexanone. The introduction of gem-dimethyl groups as well as incorporation of oxygen in the cyclohexanone ring in the left hand portion of the molecule elevated the potency 10-fold. In the right hand portion of the molecule, the activity was promoted 5-fold when the NH-group on the pyrazolone was replaced by oxygen atom.

Ochiai et al. [87] synthesized several 4,4-dimethylpyrazolone analogues as cyclic 30,50-nucleotide PDE 3/4-inhibitor, in which the compound 179 (Fig. 19) was demonstrated to be the most potent compound inhibiting PDE 3A and PDE 4B with the IC<sub>50</sub> values of 0.14 and 0.15 µM, respectively. In addition, significant bronchodilatory activity was observed. SAR study demonstrated that the presence of pyrazolopyridine 7-substituent can engender potency for the inhibition of PDE 4, and the isosteric imidazopyridine substitution made for the pyrazolopyridine subunit increases the well-balanced dual of PDE 3 and PDE 4. As a member of PDEs, Trypanosoma brucei PDB1 (TbrPDEB1) was described as a crucial target for the therapy of Human African trypanosomiasis [134,135], which was a parasitic disease caused by the protozoan pathogen T. brucei. Orrling and colleagues [136] explored catechol pyrazolones as trypanocidals inspired from the structural motif rolipram. After the scaffold merging, the premier potent compound 180 (Fig. 19) was selected with the TbrPDEB1 IC<sub>50</sub> value of 12 µM. Furthermore, with the help of homology modeling and docking studies to guide fragment growing into the parasite-specific P-pocket, which was a unique sub-pocket that extended from the invariant glutamine (Gln 874) through the protein to the solvent in the enzyme binding site, the fragment growing compound 181 (Fig. 19) was emerged with the outstanding activities for inhibiting T. brucei rhodesiense with IC<sub>50</sub> value of 60 nM and TbrPDEB1 with IC<sub>50</sub> value of 49 nM. SAR investigation elucidated that pyrazolone held a conjugated π-system and additional possibility to interact with aromatic residues in the binding pocket of TbrPDEB1. Moreover, the extended alkyl chain in the analogues of 181 enabled to reach and enter the P-pocket, which displaced water from the length of the P-pocket and placed the tetrazole at the solvent-exposed exit of the pore. The tetrazole in compound 181 formed a H-bond with Tyr 845, further stabilizing the conformation. Afterwards, according to the structure of 180 and 181, Amata and co-workers [137] designed and synthesized a cluster of derivatives, while poor inhibitory effect was detected, the most promising pyrazolone compound 182 (Fig. 19) only showed inhibition for 18% at the dose of 10 µM, indicating a better understanding of the subtle structural features was necessary for an optimal enzyme inhibition.

Yi and co-workers [138] synthesized the diversified pyrazolone derivatives and screened the aromatase inhibition effect. The most active compounds were 183 and 184 (Fig. 19), showing IC<sub>50</sub> values of 2.3 nM and 3.3 nM, respectively. The inhibition of compound 183 was even stronger than the reference letrozole (IC<sub>50</sub>: 2.8 nM). SAR analysis indicated that the pyrazolone moiety could inhibit aromatase by binding to its active site. The bioactivity result proved

![Fig. 19. Pyrazolone as protein inhibitors.](image-url)
that the presence of substitutions in compounds 183 and 184 were good for the inhibition, as for the most promising compound 183, the cyano group was revealed to interact with the important residues Arg 115 and Met 374 of the aromatase.

From the high-throughput screening of DMTI [139], pyrazolone hit 185 (IC50: 2.57 μM, Fig. 19) was elaborated as the structural motif. Preliminary hit-to-lead efforts gave the pyridyl analogue 186 (IC50: 1.53 μM), which imparted several undesirable features including most notably an extended conjugation motif affording an intense orange color as well as Michael acceptor features at the benzylidene ω-carbon. Further investigation introduced more substitutions to modify these skeletons, and the most promising compound 187 (IC50: 0.64 μM) was distinguished because of its eminent absorption, distribution, metabolism and excretion (ADME) properties, the inhibition of CYP3A4 was significantly reduced and the rat microsome metabolic stability was markedly hoisted compared to the precursor 186. SAR of the analogues of 187 implied that EWGs on the benzene ring were slightly preferred over electron-donating ones.

Based on the existing TGFβR1 inhibitors, Guckian and colleagues [140] described a series of TGFβR1 kinase inhibitors including a pyrazolone group which allowed replacement of the ubiquitous nitrogen H-bond acceptor within the core with a carbonyl without remarkable loss in biochemical activity. The most active compound 188 (Fig. 19) inhibited the TGFβR1 kinase with the Ki value of 0.012 μM and suppressed the PAI-Luc with the IC50 value of 0.22 μM. SAR can be recapitulated that the carbonyl moiety of pyrazolone was potent to capture the H-bonding interaction with the key residue Lys 232 of TGFβR1. The A ring was the area the authors paid attention to modify, and they found that when A ring was substituted as pyridine ring could elevate the activity because it contained a basic nitrogen in the 2-position to occupy the hydrophobic pocket. As for the aromatics on A ring, substitutions on meta position was proved to be superior to ortho or para position, and this position was very sensitive to the nature of substitution with preference for small hydrophobic substituent groups without branching on the ω-carbon, considering to influence of the size of substituted atom on the hydrophobic pocket, bromo group was selected for the suitable substitution for further investigation.

Asymmetric synthesis asymmetric spiro-pyrazolone derivatives have been a hotspot in recent years, while the investigations of bioactivity about these productions and the relationships between their enantiosomerism and activity are still rare. Bao et al. [141] synthesized a series of dispiroheterocyclic scaffold derivatives and screened the inhibitory effects against hCE1. It is worth noting that the most potent compound 189 (Fig. 19), in which there were two chiral centers important for inhibitory potency, exerted the strong inhibition with IC50 value of 0.39 μM, whose activity was 20-fold stronger than its enantiomer, indicating the importance of asymmetric [3 + 2] cyclization process.

4. Conclusion and perspective

Pyrazolone core is one of the most explored precursors among diverse fused heterocycles, capable of multiple roles in different pathophysiological conditions. According to the concept of generalized biososteres [142,143], as a typical synthetic rather than natural motif in medicinal chemistry, pyrazolone is potential to replace multiple moieties with similar chemical structure and bioactivities including parazole, imidazolin-5-one and 2,4-dihydro-1,2,4-triazol-3-one, etc., providing an important scaffold for drug development. Being a versatile molecule with immense biological significance, pyrazolone derivatives are being developed for several pathological screening including antimicrobial, antitumor, CNS effect, anti-inflammatory, antioxidant, antitubercular, antiviral and protein inhibitors activities since long.

The development of pyrazolone derivatives can be regarded as the epitome of medicinal chemistry, starting from antipyrine, several analogues have been explored and the precursor designing methods have evolved from structural modification to Fragment Based Drug Design and high-throughput screening simultaneously. With the development of science, machine learning, virtual screening and combinatorial chemistry technologies shorten the time of filtrating the leading compounds and will play a more and more important role in drug design in the future [144,145]. Investigations for privileged scaffold from the perspective of SAR have been lasting several years [146–151]. It is probable that pyrazolone scaffold has its position in the establishment of compound library due to its good drug-like and broad bioactive properties. Moreover, as we mentioned in this article, the pyrazolone group maintains properties like aromatic and it is feasible to form pi-alkyl effect with residues in the potential target, and the carbonyl group in pyrazole is a favorable hydrogen acceptor which is feasible to form potential H-bond, which provide evidence for the importance of pyrazolone structural motif in medicinal chemistry.

Pan Assay Interference Compounds studies consider that some poor drug-likeness compounds bring false positive results [152,153], but pyrazolone is not on the list. Besides, the toxicity of pyrazolone derivatives is still alarming [154], because the loss and harm caused by the side effects of antipyrine and aminopyrine including leukopenia and agranulocytosis are still vivid. In this review, we have disclosed recent role of pyrazolones in the field of medicinal chemistry by discussing insights of SAR studies and binding conformations of these heterocycle compounds with a variety of targets. These intelligences are helpful to explore novel pyrazolone analogues for the challenging pathophysiological conditions nowadays.

Declaration of competing interest

None of the authors have any conflict of interest to disclose.

Acknowledgements

This work was supported by the Changjiang Scholars and Innovative Research Team in Universities, Ministry of Education of China (IRT_15R55), the 9th Group of Hundred-Talent Program of Shaanxi Province (2017), the International Science & Technology Cooperation Program of Shaanxi Province (No. 2019KWZ-001), and Natural Science Foundation of Shaanxi Province, China (Grant No. 2017JM8054).

Abbreviations

| Abbreviation | Definition |
|--------------|------------|
| A549         | lung cancer cell lines |
| ABTS         | 2,2’-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) |
| AChE         | acetylcholine |
| AD           | Alzheimer’s disease |
| ADME         | absorption, distribution, metabolism and excretion |
| ALS          | amyotrophic lateral sclerosis |
| ALK          | anaplastic lymphoma kinase |
| AMP          | Adenosine monophosphate |
| AMPK         | AMP-activated protein kinase |
| Arg          | arginine |
| A. niger     | Aspergillus niger |
| BNV          | buffalo pox virus |
| BCZ          | benzodiazepine |
| Caco-2       | the human colon carcinoma cell line |
| C. albicans  | Candida albicans |
| CLint        | clearance rate |


References

[1] S.G. Kucukguzel, S. Senkarde, Recent advances in bioactive pyrazoles, Eur. J. Med. Chem. 97 (2015) 786–815.
[2] P.A. Lapchak, A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? Expert Opin. Pharmacother. 11 (2010) 1753–1763.
[3] F. Mesattini, L. Prencipe, F. Bardelli, G. Giannini, P. Tarli, The 4-hydroxybenzoate/4-aminophenol chromogenic system used in the enzymatic determination of serum cholesterol, Clin. Chem. 24 (1978) 2161–2165.
[4] J.B. Bussel, G. Cheng, M.N. Saleh, B. Psaila, J. Kloczko, H. Hassani, B. Mayer, N.L. Stone, M. Arning, D. Provan, J.M. Jenkins, Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N. Engl. J. Med. 357 (2007) 2237–2247.
[5] J.G. McHutchison, G. Durieux, M. Rodriguez-Torres, S. Sigal, M. Bourliere, T. Berg, S.C. Gordon, F.M. Campbell, D. Theodore, N. Blackman, J. Jenkins, N.N. Alif, T.P.L. Grp, Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C, N. Engl. J. Med. 357 (2007) 2227–2236.
[6] F.G. Freitag, R. Cady, F. DiSerio, B. Ehrenreich, M. Goldstein, J.A. Clapper, A.M. Rapoport, C. Sadowsky, J.R. Saper, T.R. Smith, Comparative study of a combination of isomethypentane, mucolipidophillic acid with acetaminophen and sumatriptan succinate in the treatment of migraine, Headache 41 (2001) 391–396.
[7] G.L. Pesceno, A. Apollo, M. Bacciardi, Sulforhodamine B in pulmonary practice, Case studies, Minerva Pediatr. 34 (1982) 39–43.
[8] M. Himly, B. Jahn-Schmid, K. Pittertshatscher, B. Bohle, K. Grumbmayr, F. Ferreira, H. Ebner, C. Ebner, Igl-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone, J. Allergy Clin. Immunol. 111 (2003) 882–888.
[9] F.D. Hart, P.L. Boardman, Trial of nifenazone (“THYLIN”), Br. Med. J. 1 (1964) 1553–1554.
[10] J.S. Casas, M.S. Garcia-Tasende, A. Sanchez, J. Sordo, A. Touceda, Coordination modes of 5-pyrazolones: a solid-state overview, Coord. Chem. Rev. 251 (2007) 1561–1589.
[11] X. Xie, L. Xiang, C. Peng, B. Han, Catalytic asymmetric synthesis of spiropyrrolidines and their application in medicinal chemistry, Chem. Rev. 19 (2019) 1–28.
[12] W.S. Hamama, H.G. El-Goehary, N. Kuhnert, H.H. Zoerob, Chemistry of pyrazolones and their applications, Curr. Org. Chem. 16 (2012) 373–399.
[13] S. Liu, X. Bao, B. Wang, Pyrazolone: a powerful synthetic for asymmetric diverse derivatizations, Chem. Commun. 54 (2018) 11515–11529.
[14] G. Franci, A. Falanga, S. Caldiero, L. Palomba, M. Rai, G. Morelli, M. Caldiero, Silver nanoparticles as potential antibacterial agents, Molecules 20 (2015) 8856–8874.
[15] A. Cukurovaci, I. Yilmaz, S. Gur, C. Kazaz, Synthesis, antibacterial and anti-fungal activity of some new thiazolopyrimidine derivatives containing 3-substituted cyanoimidazol-4-yl, Eur. J. Med. Chem. 41 (2006) 261–267.
[16] A.S. Chaudhary, A. Review of global initiatives to combat antibiotic resistance and recent antibiotics’ discovery, Acta Pharm. Sin. B 6 (2016) 552–556.
[17] H. Jiang, M. Xiong, Q. Bi, Y. Wang, C. Li, Self-enhanced targeted delivery of a novel chitosan nanogel for breast cancer treatment, Headache 41 (2001) 391–396.
[18] Z. Guo, Discovery of imrecoxib, Chin. J. N. Drugs 21 (2012) 223.
[19] H.M. Aly, N.M. Saleh, H.A. Elhady, Design and synthesis of some new thiosemicarbazide pyrazolones, Ann. Pharm. Fr. 72 (2014) 101.
[20] A.L. Rheingold, S.M. Kwasny, T.J. Opperman, Detour of prenostodione synthesis towards pyrazolones, J. Heterocycl. Chem. 49 (2012) 543.
[21] N. Soliman, H.H. Zoorob, A versatile synthesis, combinatorial array, and recent antibiotics’ discovery, Acta Pharmacol. Sin. B 6 (2016) 1021–1027.
[22] A.M. Akondi, M.L. Kantam, R. Trivedi, J. Bharatam, S.P.B. Vemulapalli, J. Chem. Neuroanat. (2013) 741953.
[23] A.A.M. Alkhaldi, M.A. Abdelgawad, B.G.M. Youssif, Synthesis, antimicrobial evaluation of some multi-functional alkylpyrazolones, Eur. J. Med. Chem. 46 (2011) 4566–4572.
[24] W.S. Hamama, H.G. El-Goehary, M. Soliman, H.H. Zoerob, A versatile synthesis, PM3-semiempirical, antibacterial, and antitumor evaluation of some bioactive pyrazolones and their application in medicinal chemistry, Curr. Org. Chem. 16 (2012) 373–399.
[25] K.H. Song, J. Yoon, S. Lee, M. Jang, A. Jung, S. Kim, S. Choy, Assessment of the potential biological activity of pyrazolones, Arch. Pharm. Res. 17 (2018) 2235.
H.H. Fahmy, W. El-Eraky, Synthesis and evaluation of the analgesic and K. Ochiai, S. Takita, A. Kojima, T. Eiraku, N. Ando, K. Iwase, T. Kishi, A. Ohinata, M.T. El Sayed, M.A.M.S. El-Sharief, E.S. Zarie, N.M. Morsy, A.R. Elsheakh, M.S. Abbady, M.S.K. Youssef, Synthesis and biological activity of some new N.A. Khalil, E.M. Ahmed, K.O. Mohamed, Y.M. Nissan, S.A.-B. Zaitone, Syn- C.H. Park, X. Siomboing, S. Yous, B. Gressier, M. Luyckx, P. Chavatte, In- M. Alonso, A. Martinez, GSK-3 inhibitors: discoveries and developments, A. Martinez, D.I. Perez, GSK-3 Inhibitors: a ray of hope for the treatment of K. Somakala, M. Amir, Synthesis, characterization and pharmacological investigations of new lead structures for the design of novel cyclooxygenase-2 D. Castagnolo, F. Manetti, M. Radi, H. Nakagawa, R. Ohyama, T. Fukuuchi, S. Ohta, T. Suzuki, A. Kimata, K. Kaupmann, J. Mosbacher, Exploring subtype selectivity and J. Blanz, K. Kaupmann, J. Mosbacher, J.C. VanRens, R.G. Bookland, C.M. Clark, J.F. Djung, S.K. Laughlin, M.P. Sabat, R.G. Bookland, J.C. VanRens, M.J. Ahsan, J.G. Samy, C.B. Jain, K.R. Dutt, H. Khalilullah, M.S. Nomani, Discovery and optimization of 1,3,4-thiadiazoles as MDR-TB inhibitors, Eur. J. Med. Chem. 167 (2019) 669–677. H. Huang, Y. Yu, Z. Gao, Y. Zhang, C. Li, X. Xu, H. Jin, W. Yan, R. Ma, J. Zhu, Yukihito Higashi, Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases, Recent Pat. Cardiovasc. Drug Discov. 1 (2006) 85–93. M.S. Alam, D-U. Lee, Synthesis, molecular structure and antioxidant activity of (E)-4-Benzylideneaniline-1.5-dimethyl-2-phenyl-H-pyrazol-3(2H)-one, a Schiff Base ligand of 4-Aminantipyrine, J. Chem. Crystallogr. 42 (2012) 71–82. K.M. Khan, A. Khan, M. Taha, U. Salar, A. Hameed, N.H. Ismail, W. Jamil, S. Chopra, D. Siram, V.N.A. Dusthackeer, H.B. Rodé, Synthesis and evaluation of alpha-aminocarboxylic acids as antituberular agents effective on drug resistant tuberculosis, Eur. J. Med. Chem. 164 (2019) 685–697. H. Patel, H. Jalilvand, I. Ansari, R. Farahani, S. Moradi, Pyridine and nitro-phenyl linked 1,3,4-thiadiazoles as MDR-TB inhibitors, Eur. J. Med. Chem. 167 (2019) 1–9. S.K. Krishna, N. Vamsi, S. Mathew, R.S. Eakambaram, L. Sivakumar, A. Natarajan, S. Palanippan, Design, synthesis, and characterization of some hybridized pyrazolone pyrophosphate analogs against Mycobacterium tuberculosis, Arch. Pharm. 349 (2016) 383–397. P. Gunasekaran, S. Perumal, P. Yogeeswar, D. Siram, A facile four-component sequential protocol in the expedient synthesis of novel 2-aryl-5-methyl-2,3-dihydro-1H-3-pyrazolones in water and their antitubercular evaluation, Eur. J. Med. Chem. 46 (2011) 4530–4536. D. Castagnolo, A. De Logu, M. Radi, B. Bechi, F. Manetti, M. Magnani, S. Speroni, R. Meleddu, M. Saddi, M. Botta, Synthesis, biological evaluation and SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis, Bioorg. Med. Chem. 16 (2008) 8587–8591. D. Castagnolo, F. Manetti, M. Radi, B. Bechi, M. Pagano, A. De Logu, R. Meleddu, M. Saddi, M. Botta, Synthesis, biological evaluation and SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis: Part 2. Synthesis of rigid pyrazolones, Bioorg. Med. Chem. 17 (2009) 5716–5721. K.S. Sivakumar, A. Rajasekharan, R. Rao, B. Narasimhan, Synthesis, SAR study and evaluation of Mannich and Schiff bases of pyrazol-5(4H)-one moieties containing 3-(Hydrazinyl)-2-phenylquinazolin-4(3H)-one, Indian J. Pharm. Sci. 75 (2013) 463–475. M.J.A. Ahsan, J.C. Mary, H. Khalilullah, M.S. Nomani, P. Sarawat, R. Gaur, A. Singh, Molecular properties prediction and synthesis of novel 1,3,4-benzodiazepine analogues as potent antimicrobial and antituberular agents, Bioorg. Med. Chem. Lett. 21 (2011) 7246–7250. M.J. Ahsan, J.G. Samy, H. Khalilullah, M.S. Nomani, Discovery of novel antituberular 1,3,5-dimethyl-2-phenyl-4-[5-(arylamino)]-1,3,4oxadiazole-2(3H)-ylmethylamine-1,2-dihydro-3H-pyrazol-3-one analogues, Bioorg. Med. Chem. Lett. 22 (2012) 803–807. Z. Zhao, H. Song, J. Xie, X. Zhao, X. Chen, H. He, S. Wu, Y. Zhang, X. Zheng, Research progress in the biological activities of 3,4,5-trimethoxycinnamic acid (TMCA) derivatives, Eur. J. Med. Chem. 173 (2019) 213–227. X. Fan, X. Zhang, L. Zou, K.A. Keith, E.R. Kern, P.F. Torrence, A pyrazinyl-pyrazolone nucleoside chimera with potent in vitro anti-orthopoxvirus activity, Bioorg. Med. Chem. Lett. 16 (2006) 3224–3228. A. Kimata, H. Nakagawa, R. Ohyama, T. Fukuuchi, S. Ohta, T. Suzuki, N. Miyata, New series of antiperoxide compounds: pyrazolone derivatives have the potent activity of inhibiting proteinase-resistant prion protein accumulation, J. Med. Chem. 50 (2007) 5053–5056. B. Simovska, B. Naneva, B. Kolakoski, V. Bhanuprakash, C.G.D. Raj P.S. Nayak, Design and synthesis of novel spiro-piperidinyl pyrazoline derivatives and their potential antiviral activity, Lett. Drug Discov. Discov. 13 (2016) 149–160. V. Kumar, K.P. Tan, Y.M. Wang, S.W. Lin, P.H. Liang, Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors, Bioorg. Med. Chem. 24 (2016) 3035–3042. S. Cassidy, B.A. Syed, Nonalcoholic steatohepatitis (NASH) drugs market, Nat. Med. J. India 2018; 31(3) 133-140. B.A. Neuenschwander-Tetri, Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontranslucide fatty acid metabolites, Hepatology 52 (2010) 774–788. H. Huang, Y. Yu, Z. Gao, L. Zhang, W. Li, X. Hu, J. Yin, R. Ma, J. Zhu, X. Shen, H. Jiang, L. Chen, J. Li, Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists, J. Med. Chem. 55 (2012) 7037–7053.
J. Henao-Mejia, E. Elinav, C. Jin, L. Hao, W.Z. Mehal, T. Strowig, C.A. Thaiss, D.G. Hardie, B.E. Schaffer, A. Brunet, AMPK: an energy-sensing pathway with S. Fiorucci, A. Mencarelli, G. Palladino, S. Cipriani, bile-acid-activated re- Y.D. Wang, W.D. Chen, D.D. Moore, W. Huang, FXR: a metabolic regulator K.M. Orrling, C. Jansen, X.L. Vu, V. Balmer, P. Bregy, A. Shanmugham, E. Chatelain, J.-R. Ioset, A. van de Stolpe, S. Zorg, J. Veerman, K.L. Whiteaker, V.E. Scott, K.L. Kees, J.J. Fitzgerald, K.E. Steiner, J.F. Mattes, B. Mihan, T. Tosi, D. Mondoro, T.M.A. Eldebss, A.M. Farag, M.M. Abdalla, A.A. Khedr, Synthesis of some new K.M. Abamak & X. Liu, Designing in molecular scaffold with potent, broad-ranging pharmacological activities, Curr. Pharmaceut. Des. 19 (2013) 7141–7154.

A. Kumari, R.K. Singh, Medicinal chemistry of indole derivatives: current to H. Ju, P. Zhan, X. Liu, Designing in molecular scaffold with potent, broad-ranging pharmacological activities, Curr. Pharmaceut. Des. 19 (2013) 1528–1548.

H. Ju, P. Zhan, X. Liu, Designing influenza polymerase acidic endonuclease inhibitors via 'privileged scaffold' re-evolution/refining strategy, Future Med. Chem. 11 (2019) 265–268.

H. Guo, N. Eleftheriadis, N. Rohr-Udilova, A. Domling, F.J. Dekker, Photocatalyst design provides a mechanistic explanation for pan-assay interference behaviour of 2-aminoypyrazoles in lipoygenase inhibition, Eur. J. Med. Chem. 139 (2017) 633–643.

A.R. Jesus, D. Yila-Vicosa, M. Machuqueiro, A.P. Marques, T.M. Dore, A.P. Rauter, Targeting type 2 diabetes with C-glucosyl dihydrochalcones as selective sodium glucose co-transporter 2 (SGLT2) inhibitors: synthesis and biological evaluation, J. Med. Chem. 60 (2017) 568–579.

X. Ju, L. Feng, Y. Liu, L. Zhang, Degradation behaviors and genetic toxicity variations of pyrazolone pharmaceuticals during chlorine dioxide disinfection process, Chem. Eng. J. 345 (2018) 156–164.